SCHEMBL12373510

SCHEMBL12373510

Cc1nc(-c2cc(C#N)c3ccncc3c2)sc1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 8/20 0.61
ABCC4 O15439 1/20 0.53
ABCB11 O95342 1/20 0.53
PGR P06401 1/20 0.53
CHRM1 P11229 1/20 0.53
PDE4A P27815 1/20 0.53
BLVRB P30043 1/20 0.53
TARBP2 Q15633 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
ABCG2 Q9UNQ0 1/20 0.53
RAB9A P51151 3/20 0.51
KDM4E B2RXH2 2/20 0.51
GAA P10253 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2185636 0.85 XDH (0.67) XDHABCC4ABCB11PGRCHRM1
SCHEMBL12316978 0.84 XDH (0.66) XDHABCC4ABCB11PGRCHRM1
SCHEMBL2184262 0.83 XDH (0.62) XDHABCC4ABCB11PGRCHRM1
SCHEMBL12316984 0.82 XDH (0.61) XDHABCC4ABCB11PGRCHRM1
SCHEMBL2185106 0.82 XDH (0.63) XDHABCC4ABCB11PGRCHRM1
SCHEMBL12317003 0.81 XDH (0.60) XDHABCC4ABCB11PGRCHRM1
SCHEMBL12316998 0.80 XDH (0.61) XDHABCC4ABCB11PGRCHRM1
SCHEMBL12316982 0.80 XDH (0.61) XDHABCC4ABCB11PGRCHRM1
SCHEMBL13382295 0.80 XDH (0.61) XDHABCC4ABCB11PGRCHRM1
SCHEMBL12317002 0.80 XDH (0.60) XDHABCC4ABCB11PGRCHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201815-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-08-18 US disclosed
US-20110201815-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES KISSEI PHARMACEUTICAL CO., LTD. (JP) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201815-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES XDH, PON1, CBR1 XDH 1/4885ABCC4 398/4885ABCB11 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.